Center for Cancer and Blood Disorders, Children's Hospital Colorado and Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Charles C. Gates Biomanufacturing Facility, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Cytotherapy. 2023 Jan;25(1):94-102. doi: 10.1016/j.jcyt.2022.09.004. Epub 2022 Oct 14.
Vector copy number (VCN), an average quantification of transgene copies unique to a chimeric antigen receptor (CAR) T-cell product, is a characteristic that must be reported prior to patient administration, as high VCN increases the risk of insertional mutagenesis. Historically, VCN assessment in CAR T-cell products has been performed via quantitative polymerase chain reaction (qPCR). qPCR is reliable along a broad range of concentrations, but quantification requires use of a standard curve and precision is limited. Digital PCR (dPCR) methods were developed for absolute quantification of target sequences by counting nucleic acid molecules encapsulated in discrete, volumetrically defined partitions. Advantages of dPCR compared with qPCR include simplicity, reproducibility, sensitivity and lack of dependency on a standard curve for definitive quantification. In the present study, the authors describe a dPCR assay developed for analysis of the novel bicistronic CD19 × CD22 CAR T-cell construct.
The authors compared the performance of the dPCR assay with qPCR on both the QX200 droplet dPCR (ddPCR) system (Bio-Rad Laboratories, Inc, Hercules, CA, USA) and the QIAcuity nanoplate-based dPCR (ndPCR) system (QIAGEN Sciences, Inc, Germantown, MD, USA). The primer-probe assay was validated with qPCR, ndPCR and ddPCR using patient samples from pre-clinical CAR T-cell manufacturing production runs as well as Jurkat cell subclones, which stably express this bicistronic CAR construct.
ddPCR confirmed the specificity of this assay to detect only the bicistronic CAR product. Additionally, the authors' assay gave accurate, precise and reproducible CAR T-cell VCN measurements across qPCR, ndPCR and ddPCR modalities.
The authors demonstrate that dPCR strategies can be utilized for absolute quantification of CAR transgenes and VCN measurements, with improved test-retest reliability, and that specific assays can be developed for detection of unique constructs.
载体拷贝数(VCN)是嵌合抗原受体(CAR)T 细胞产品中转基因拷贝数的平均量化指标,在给药前必须报告,因为高 VCN 会增加插入突变的风险。传统上,CAR T 细胞产品中的 VCN 评估是通过定量聚合酶链反应(qPCR)进行的。qPCR 在广泛的浓度范围内是可靠的,但定量需要使用标准曲线,并且精度有限。数字 PCR(dPCR)方法是为通过对离散、体积定义的分区内封装的核酸分子进行计数而开发的,用于目标序列的绝对定量。与 qPCR 相比,dPCR 的优点包括简单性、可重复性、灵敏度和无需标准曲线即可进行明确定量。在本研究中,作者描述了一种用于分析新型双顺反子 CD19×CD22 CAR T 细胞构建体的 dPCR 测定法。
作者比较了 QX200 液滴式 dPCR(ddPCR)系统(Bio-Rad Laboratories,Inc.,美国加利福尼亚州赫拉克勒斯)和 QIAcuity 基于纳米板的 dPCR(ndPCR)系统(QIAGEN Sciences,Inc.,美国马里兰州日耳曼敦)上的 dPCR 测定法与 qPCR 的性能。使用来自临床前 CAR T 细胞制造生产运行的患者样本以及稳定表达这种双顺反子 CAR 构建体的 Jurkat 细胞亚克隆,通过 qPCR、ndPCR 和 ddPCR 对引物探针测定法进行了验证。
ddPCR 证实了该测定法特异性检测双顺反子 CAR 产物。此外,作者的测定法在 qPCR、ndPCR 和 ddPCR 模式下均能准确、精确且可重复地测量 CAR T 细胞 VCN。
作者证明 dPCR 策略可用于 CAR 转基因的绝对定量和 VCN 测量,具有更高的测试-再测试可靠性,并且可以开发特定的测定法来检测独特的构建体。